Office of Science & Technology - Harald Isemann: Building an Optimal Framework for World-Class Biotechnology Research
Menu Content/Inhalt

Podcast

This is the subscription link for bridges podcasts.

podcast
Please find more information in the podcast section
Harald Isemann: Building an Optimal Framework for World-Class Biotechnology Research Print E-mail

by Eleonora Windisch


Administrative Director
Research Institute of Molecular Pathology (IMP)
Vienna, Austria


This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Harald Isemann was named Administrative Director of the privately-funded Institute of Molecular Pathology (IMP) in Vienna in February 2004. IMP is a subsidiary of Boehringer Ingelheim, one of the world’s leading pharmaceutical companies. Headed by Prof. Kim Nasmyth, the Institute is a basic biomedical research center and is located within the Campus Vienna BioCenter, a center for molecular biology and genetic research. “My experience working with Technologie Impulse Ltd. (TIG), enabled me to acquire the necessary expertise for my current position at IMP,” Mr. Isemann said, adding, “IMP’s reputation as one of Europe’s leading research institutions made the job offer particularly attractive for me.”


Access to the full article is free, but requires you to register. Registration is simple and quick – all we need is your name and a valid e-mail address. We appreciate your interest in bridges.

 
Back to Top